Praziquantel nano-powder as well as preparation method and application thereof
Through ultrafine crushing and nanotechnology treatment, praziquantel nanopowder was prepared, which solved the problems of inconvenience in use and low bioavailability of praziquantel powder in the prior art, and achieved efficient and economical therapeutic effects and safety of livestock products. promote.
Patent Information
- Application Number
- CN202411163067.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
As a hard-to-soluble drug, praziquantel has inconvenient use and low bioavailability in the prior art, resulting in poor efficacy, large dosage and high drug resistance.
Nano-grade praquantel powder is prepared by ultra-fine crushing, adding stabilizers, solubilizers, surfactants, emulsifiers, dispersants and other adjuvants for grinding, shearing and emulsification, and nano-grade praquantel powder is prepared by spray drying technology. Ensure the nanoparticle size is restored when dissolved in water.
It improves the bioavailability of praziquantel, simplifies the use method, reduces the dosage, reduces drug resistance and drug residues, and improves the safety, quality and economic benefits of livestock products.
Smart Images

Figure BDA0005007006680000071 
Figure BDA0005007006680000081 
Figure BDA0005007006680000091
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of veterinary chemical drugs, and more specifically to a praziquantel nano powder, a preparation method and an application thereof. Background Art
[0002] Praziquantel is an anthelmintic for humans and animals, specifically for the treatment of tapeworms and flukes, and is particularly effective against schistosoma japonicum, Chinese liver fluke, and Diphyllobothrium luxuriatum, and is widely used in countries around the world. According to the Chinese veterinary drug standards, there are two dosage forms of praziquantel tablets and praziquantel powder (50%) for cattle, sheep, pigs, dogs, cats and poultry. For oral administration: a single dose of 20-70 mg per kg of body weight for cattle, sheep, and pigs, and 5-10 mg for dogs and cats, which plays an important role in the prevention and treatment of animal tapeworms and schistosoma japonicum.
[0003] However, in actual application, it is found that: praziquantel tablets are first ground into powder and directly administered or mixed into feed for feeding, and praziquantel powder is mixed into feed when used, which is extremely inconvenient to use and requires a large dosage.
[0004] The results of the test of using praziquantel orally to treat artificial schistosomiasis infection in cattle by Shanghai Institute of Schistosomiasis, Chinese Academy of Agricultural Sciences and other units showed that the efficacy of praziquantel powder (tablet) 25mg / Kg body weight once orally was poor, with a worm reduction rate of 86.1%, a female worm reduction rate of 95.8%, and cysts in the remaining worms. It can be seen that the minimum effective dose of praziquantel powder or tablets once orally to treat schistosomiasis in cattle is 30mg / Kg body weight (Wu Qingli 1980).
[0005] Jiangsu Animal Husbandry and Veterinary Research Institute and other institutions conducted experimental research on the treatment of goat schistosomiasis with praziquantel powder, which showed that the worm reduction rate and female worm reduction rate of infected goats were 100.0% after oral administration of 60mg / Kg or 40mg / Kg of praziquantel once, and the worm reduction rate and female worm reduction rate were 99.8% and 100.0% respectively after oral administration of 20mg / Kg of praziquantel once. There was no obvious therapeutic effect after oral administration of 10mg / Kg or 5mg / Kg of praziquantel once (Fan Biqin et al. 1980). It can be seen that the minimum effective dose of 20mg / Kg of body weight for the treatment of goat and sheep schistosomiasis with praziquantel once is 10mg / Kg of body weight.
[0006] In the Biopharmaceutical Classification System (BCS), praziquantel is classified as a Class II active pharmaceutical ingredient, which means that the drug has low water solubility and high permeability through the intestinal membrane. In addition, due to its low solubility and high metabolic rate, it is also classified as a Class II drug in the Biopharmaceutical Drug Disposition Classification System (BDDCS). Due to these unfavorable properties, these drugs may have serious oral absorption problems, which may lead to reduced bioavailability.
[0007] The development and utilization of praziquantel as a poorly soluble drug uses nanotechnology to reduce particle size, improve solubility and dissolution, and improve bioavailability, thereby achieving drinking water administration and reduced dosage. In the prior art, the preparation method of praziquantel powder is only a mixture of praziquantel raw materials and auxiliary carriers, and no special reports or patents on the preparation method of praziquantel nanopowder have been found.
[0008] Therefore, providing a method for preparing praziquantel nanopowder is an urgent problem to be solved by those skilled in the art. Summary of the invention
[0009] In view of the above problems, in order to facilitate use, administer the drug by drinking water, maximize the bioavailability of the drug, improve the efficacy, reduce the dosage, reduce drug resistance, reduce drug residues, improve the safety and quality of livestock products, and better serve the animal husbandry industry, the present invention discloses a praziquantel nano powder and a preparation method and application thereof. In the present invention, praziquantel is subjected to ultrafine grinding, and adjuvants such as stabilizers, solubilizers, surfactants, emulsifiers, and dispersants are added to perform nano-series process such as grinding, shearing, and emulsification. After the particle size of decoquinate reaches the nanometer standard, it is spray-dried to obtain the nanometer particle size, and when dissolved in water for use, the nanometer particle size can be restored.
[0010] One of the purposes of the present invention is to provide a method for preparing a praziquantel nanopowder, comprising the following steps:
[0011] (1) Weigh a certain amount of praziquantel and add it to an ultrafine grinder to obtain D 50 5-15μm, D 90 20-40 μm praziquantel, for later use;
[0012] (2) Weigh a certain amount of HPMC and PVPK 30 , sodium lauryl sulfate, dimethyl silicone oil, add purified water to obtain a clear and transparent solution A for standby use;
[0013] (3) Weigh a certain amount of poloxamer, HPMC, and RH 40 , β-cyclodextrin, add purified water to obtain a clear and transparent solution B for later use;
[0014] (4) Add praziquantel to solution A and grind thoroughly to obtain a particle size D 50 100-300nm, D 90 400-600nm praziquantel suspension C;
[0015] (5) Add solution B to praziquantel suspension C, shear and stir, and measure the particle size D of praziquantel. 50 100-300nm, D 90 400-600nm, to obtain praziquantel nanosuspension D;
[0016] (6) The praziquantel nanosuspension D is spray dried, powdered, and passed through a 300-mesh sieve to obtain a praziquantel nanopowder.
[0017] Preferably, the praziquantel in step (1) and the HPMC and PVPK in step (2) 30 The mass ratio of sodium dodecyl sulfate, dimethyl silicone oil and purified water is (20-40):(0.2-0.4):(0.1-0.3):(0.25-0.75):(1.5-4.5):100.
[0018] The beneficial effects of adopting the above technical solution are: the above raw material combination and ratio are an organic combination of surfactants, stabilizers and defoamers, so that the particle size of the praziquantel nanosuspension is more uniform and the production efficiency is higher during the preparation process, which is the material basis for successfully restoring the nanoparticle size after dissolving in water after powdering.
[0019] Preferably, the praziquantel in step (1) and the poloxamer, HPMC, RH in step (3) 40 The mass ratio of β-cyclodextrin and purified water is (20-40):(4-6):(1-3):(2-4):(11-21):100.
[0020] The beneficial effects of adopting the above technical solution are: the above raw material combination and ratio are stable carriers of praziquantel nanoparticles, which are necessary conditions for improving the spray drying powder production yield and production efficiency of praziquantel nanosuspension.
[0021] The beneficial effects of solution A and solution B on nano products are as follows: solution A is a stabilizing system of surfactants, dispersants and defoamers, and solution B is a carrier of praziquantel. The two ensure that praziquantel nano powder is smoothly made into a nano suspension during the preparation process and the nano particle size is successfully restored after the spray powder is dissolved in water.
[0022] Preferably, in step (4), the grinding equipment is selected from a colloid mill, a high-pressure homogenizer, and a sand mill, and the grinding time is 2-4 hours.
[0023] Preferably, in step (5), the shearing and stirring conditions are 2900 r / min, 40-60 min.
[0024] The beneficial effects of adopting the above technical solution are: grinding is the way to change the particle size of praziquantel to nanometers, and shearing and stirring make the praziquantel nanosuspension mixed more evenly and dispersed more uniformly.
[0025] Preferably, in step (6), the spray drying is set with an inlet air temperature of 100-130°C (preferably 110-120°C), an outlet air temperature of 60-90°C (preferably 70-80°C), a steam pressure of 0.05-0.10MPa, a nozzle pressure of 0.03-0.05MPa, and a pressure tank temperature of 60-90°C.
[0026] The beneficial effect of the above-mentioned spray drying on the nano-product is that it makes it possible to evenly suspend praziquantel in water, thus solving the problem that praziquantel is insoluble in water.
[0027] The second object of the present invention is to provide a praziquantel nanopowder.
[0028] Preferably, the praziquantel nano powder is dissolved in water at a mass ratio of 1:100, and the praziquantel particle size D is detected by a laser particle size analyzer. 50 100-300nm, D 90 400-600nm.
[0029] The technical concept of the present invention is that praziquantel itself is insoluble in water. The present invention uses nanotechnology to make the particle size of praziquantel reach the nanoscale. The raw material formula used in the preparation, on the one hand, helps praziquantel reach the nanoparticle size, and on the other hand, makes praziquantel soluble in water and exist in a nano state after being spray-dried into powder, thereby improving bioavailability.
[0030] The third object of the present invention is to provide an application of praziquantel nanopowder, and the application of praziquantel nanopowder in anthelmintics for tapeworms and trematodes of cattle, sheep, pigs, poultry, dogs and cats.
[0031] The application of the praziquantel nano powder of the present invention maximizes the bioavailability of the drug, improves the efficacy, reduces the dosage, reduces drug resistance, reduces toxic and side effects, reduces drug residues, improves the safety and quality of livestock products, and has significant economic and social benefits.
[0032] It can be seen from the above technical scheme that, compared with the prior art, the beneficial effects of the present invention are as follows: praziquantel nanopowder is highly dispersible, suspended in water, easy to use, high in bioavailability, small in dosage, short in peak time, high in blood drug concentration, and high in cost performance. Therefore, it is particularly suitable for the treatment of tapeworms and trematodes in cattle, sheep, pigs, poultry, dogs, and cats, is easy to use, reduces the cost and the risk of drug resistance, has low drug residues, and ensures the safety of livestock products. DETAILED DESCRIPTION
[0033] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] Example 1
[0035] A method for preparing a praziquantel nano powder comprises the following steps:
[0036] (1) Weigh 20 kg of praziquantel and grind it into ultrafine powder in an ultrafine grinder to obtain D 50 5μm, D 90 20 μM praziquantel.
[0037] (2) Weigh 0.2 kg of HPMC and PVPK 30 0.1 kg, 0.25 kg of sodium lauryl sulfate, 1.5 kg of dimethyl silicone oil, add 100 kg of purified water to make a clear solution A for standby use.
[0038] (3) Weigh 4 kg of poloxamer, 1 kg of HPMC, and RH 40 2 kg, 11 kg of β-cyclodextrin, add 100 kg of purified water to make a clear and transparent solution B for later use.
[0039] (4) adding the praziquantel obtained in step (1) to the standby solution A obtained in step (2), and grinding the solution for 2 hours using a colloid mill, a sand mill, etc. to obtain a particle size D 50 100, D 90 400 C of praziquantel suspension.
[0040] (5) The suspension C obtained in step (4) was added to the solution B in step (3), and the mixture was sheared and stirred at 2900 rpm for 40 minutes to detect the particle size D of praziquantel. 50 100nm, D 90 400, to obtain praziquantel nanosuspension D.
[0041] (6) The praziquantel nanosuspension D obtained in step (5) is transported to a spray drying tower through a pipeline, and the air inlet temperature is set to 110-120°C, the air outlet temperature is 70-80°C, the steam pressure is 0.05MPa, the nozzle pressure is 0.03MPa, and the pressing tank temperature is 70-80°C. The praziquantel nanosuspension D is sprayed, powdered, and passed through a 300-mesh sieve. The moisture content is controlled to 4.0%. The praziquantel nanosuspension D is dissolved in water at a mass ratio of 1:100. The praziquantel particle size D is measured using a laser particle size analyzer. 50 100nm, D 90 400nm, to obtain praziquantel nanopowder.
[0042] Example 2
[0043] A method for preparing a praziquantel nano powder comprises the following steps:
[0044] (1) Weigh 30 kg of praziquantel and grind it into ultrafine powder in an ultrafine grinder to obtain D50 10μm, D 90 30 μM praziquantel.
[0045] (2) Weigh 0.3 kg of HPMC and PVPK 30 0.2 kg, 0.50 kg of sodium lauryl sulfate, 3 kg of dimethyl silicone oil, add 100 kg of purified water to make a clear solution A for standby use.
[0046] (3) Weigh 5 kg of poloxamer, 2 kg of HPMC, and RH 40 3 kg, 16 kg of β-cyclodextrin, add 100 kg of purified water to make a clear and transparent solution B for later use.
[0047] (4) Add the praziquantel obtained in step (1) to the standby solution A obtained in step (2), and grind for 3 hours using a colloid mill and a high-pressure homogenizer to obtain a particle size D 50 200, D 90 500 C of praziquantel suspension.
[0048] (5) The suspension C obtained in step (4) was added to the solution B in step (3), and the mixture was sheared and stirred at 2900 rpm for 50 minutes to detect the particle size D of praziquantel. 50 200nm, D 90 500, to obtain praziquantel nanosuspension D.
[0049] (6) The praziquantel nanosuspension D obtained in step (5) is transported to a spray drying tower through a pipeline, and the air inlet temperature is set to 100-110° C., the air outlet temperature is 60-70° C., the steam pressure is 0.75 MPa, the nozzle pressure is 0.05 MPa, and the pressing tank temperature is 60-80° C. for spraying, powdering, and passing through a 300-mesh sieve. The moisture content is controlled to 4.0%, and the praziquantel nanosuspension D is dissolved in water at a mass ratio of 1:100. The praziquantel particle size D is measured using a laser particle size analyzer. 50 200nm, D 90 500nm, to obtain praziquantel nanopowder.
[0050] Example 3
[0051] A method for preparing a praziquantel nano powder comprises the following steps:
[0052] (1) Weigh 40 kg of praziquantel and grind it into ultrafine powder in an ultrafine grinder to obtain D 50 15μm, D 90 40 μM praziquantel.
[0053] (2) Weigh 0.4 kg of HPMC and PVPK 300.3 kg, 0.75 kg of sodium dodecyl sulfate, 4.5 kg of dimethyl silicone oil, add 100 kg of purified water to make a clear solution A for standby use.
[0054] (3) Weigh 6 kg of poloxamer, 3 kg of HPMC, and RH 40 4 kg, 21 kg of β-cyclodextrin, add 100 kg of purified water to make a clear and transparent solution B for standby use.
[0055] (4) Add the praziquantel obtained in step (1) to the standby solution A obtained in step (2), and grind for 4 hours using a sand mill and a high-pressure homogenizer to obtain a particle size D 50 300, D 90 600 C of praziquantel suspension.
[0056] (5) The suspension C obtained in step (4) was added to the solution B in step (3), and the mixture was sheared and stirred at 2900 rpm for 60 minutes to detect the particle size D of praziquantel. 50 300nm, D 90 600, to obtain praziquantel nanosuspension D.
[0057] (6) The praziquantel nanosuspension D obtained in step (5) is transported to a spray drying tower through a pipeline, and the air inlet temperature is set to 120-130° C., the air outlet temperature is 80-90° C., the steam pressure is 0.10 MPa, the nozzle pressure is 0.05 MPa, and the pressing tank temperature is 80-90° C., and spraying, powdering, and passing through a 300-mesh sieve are performed. The moisture content is controlled to 4.0%, and the praziquantel nanosuspension is dissolved in water at a mass ratio of 1:100. The praziquantel particle size D is measured using a laser particle size analyzer. 50 300nm, D 90 600nm, to obtain praziquantel nanopowder.
[0058] Test example
[0059] (I) Observation on the long-term stability of praziquantel nanopowder
[0060] 1. Strong light irradiation test
[0061] The purpose of the strong light irradiation test is to provide a basis for the packaging and storage conditions of praziquantel nanopowder. The test sample is placed in a comprehensive drug stability test box under an illumination of 4500±500Lx for 10 days. Samples are taken on the 5th and 10th days respectively. The key stability inspection items, such as content, properties, 1:100 water-soluble particle size (D 50 , D 90 ), sedimentation volume ratio, etc.
[0062] The results of the content, properties, 1:100 water-soluble particle size and sedimentation volume ratio of praziquantel nanopowder in the strong light irradiation test are shown in Table 1. The results of the strong light irradiation test show that under the condition of illumination of 4500±500Lx, when the test was carried out to the 10th day, there was no significant change in the content; no significant change in the properties; no significant change in the water-soluble particle size; and no significant change in the sedimentation volume ratio. The above results show that the quality of praziquantel nanopowder is stable after the strong light irradiation test.
[0063] Table 1 Strong light irradiation test results
[0064]
[0065] 2 Accelerated test
[0066] The accelerated test is conducted under extraordinary conditions. Its purpose is to predict the stability of praziquantel nanopowder by accelerating the chemical or physical changes of praziquantel nanopowder, and to provide necessary information for its application for production, transportation and storage. According to the guidance of drug stability test in the Chinese Veterinary Pharmacopoeia, the test sample is placed at 40±2℃ and relative humidity of 75±5% for 6 months. Samples are taken at the end of 1 month, 2 months, 3 months and 6 months respectively, and key stability inspection items such as content, properties, water-soluble particle size and sedimentation volume ratio are tested.
[0067] In the accelerated test at a temperature of 40°C and a relative humidity of 75%, the test results of the content, properties, water-soluble particle size and sedimentation volume ratio of the praziquantel nanopowder are shown in Table 2. It can be seen from Table 2 that the quality of the praziquantel nanopowder is stable after the accelerated test within 6 months.
[0068] Table 2 Accelerated test results
[0069]
[0070] In summary, the praziquantel nano powder of the present invention has been shown through stability tests and accelerated tests to have high preparation stability and is a stable veterinary nano preparation that can be produced on a large scale.
[0071] (II) Pharmacokinetic comparison of praziquantel nanopowder and commercially available praziquantel powder
[0072] 1. Test methods
[0073] 24 healthy and good dairy goats (male) were selected, with an average weight of 15.35±3.49kg, ear-marked, numbered 1 to 24, and divided into 4 groups of 6, with group 1 being the test group of Example 1, group 2 being the test group of Example 2, group 3 being the test group of Example 3, and group 4 being the test group of commercially available praziquantel powder. According to the 30.0mg / Kg body weight standard, the praziquantel nano powder obtained in Example 1, Example 2, and Example 3 and the test group corresponding to the commercially available praziquantel powder were respectively administered. 5mL was collected from the anterior vena cava plexus of the goats at 0h before administration and 0.083h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, and 36h after administration, respectively, and the plasma was separated by centrifugation at 3000r / min for 10min, and stored at -20°C for later use.
[0074] The samples were processed and tested using high performance liquid chromatography, triple quadrupole mass spectrometer, benchtop centrifuge, analytical balance, etc. WinNonlin TM The plasma pharmacokinetic parameters were analyzed using the non-compartmental model in 8.1 software, and the results were expressed as mean ± standard deviation. The relative bioavailability was calculated based on the pharmacokinetic parameter results.
[0075] 2. Test results
[0076] The measured blood drug concentration time data were calculated using WinNonlin TM The plasma pharmacokinetic parameters were analyzed using the non-compartmental model in 8.1 software. The results are shown in Table 3.
[0077] Table 3 Plasma pharmacokinetic parameters
[0078]
[0079] In summary, the pharmacokinetic test of the praziquantel nano powder of the present invention is compared with that of the commercially available praziquantel powder: the peak time is advanced by 0.18 to 0.35 h, the peak concentration is 1.26 to 1.94 times, the half-life is 1.64 to 3.94 h longer, the area under the drug-time curve is 1.49 to 2.06 times higher, and the relative bioavailability is 149.00 to 206.42%, indicating that the praziquantel nano powder is a highly efficient veterinary preparation with a shorter peak time, a higher peak concentration, a longer half-life and a higher bioavailability than the commercially available praziquantel powder.
[0080] (III) Clinical application effect of praziquantel nanopowder
[0081] 1. The therapeutic effect of praziquantel nanopowder in the treatment of schistosomiasis in cattle
[0082] 16 healthy, good-condition, and similar-weight yellow cattle (male) were selected, with an average weight of 248.90±5.08kg, and each cattle was artificially infected with 500 schistosome cercariae. 45 days after infection, all feces were positive. Ear marks were used, numbered 1 to 16, and each group of 4 was divided into 4 groups, with group 1 being the test group of Example 1, group 2 being the test group of Example 2, group 3 being the test group of Example 3, and group 4 being the test group of commercially available praziquantel powder.
[0083] The samples prepared by Examples 1, 2 and 3 of the present invention were orally fed at 15 mg / Kg body weight, 20 mg / Kg body weight, 25 mg / Kg body weight, and commercially available praziquantel powder was orally fed once at 30 mg / Kg body weight. Feces were examined daily after medication, and the necropsy was performed 45 days later. The worms were collected and counted using non-excised worm bodies of the gastrointestinal tract blood vessels, and the adult rate, worm reduction rate and female worm reduction rate were calculated. The clinical effects are shown in Table 4.
[0084] Table 4 Clinical effect of praziquantel nanopowder in treating schistosomiasis in cattle
[0085]
[0086] As can be seen from Table 4, when the dosage is lower than that of the commercially available praziquantel powder, the therapeutic effects of Examples 1, 2, and 3 of the present invention are significantly higher than those of the commercially available praziquantel powder, and the dosage of Example 1 < Example 2 < Example 3, indicating that Example 1 has the highest cost-effectiveness.
[0087] 2. The therapeutic effect of praziquantel nanopowder in the treatment of goat schistosomiasis
[0088] 16 healthy, good-condition, similar-weight dairy goats (male) were selected, with an average weight of 24.78±4.15 kg, and each goat was artificially infected with 500 cercariae of Schistosoma japonicum. 45 days after infection, all fecal examinations were positive. Ear marks were used, numbered 1 to 16, and each group of 4 was divided into 4 groups, with Group 1 being the test group of Example 1, Group 2 being the test group of Example 2, Group 3 being the test group of Example 3, and Group 4 being the test group of commercially available praziquantel powder.
[0089] The samples prepared by Examples 1, 2 and 3 of the present invention were orally administered at 10 mg / Kg body weight, 15 mg / Kg body weight, 10 mg / Kg body weight, and commercially available praziquantel powder was orally administered once at 20 mg / Kg body weight. Feces were examined daily after medication, and the subjects were dissected 45 days later. The worms were collected and counted using non-excised worm bodies of the gastrointestinal tract blood vessels, and the adult rate, worm reduction rate and female worm reduction rate were calculated. The clinical effects are shown in Table 5.
[0090] Table 5 Clinical effect of praziquantel nanopowder in treating goat schistosomiasis
[0091]
[0092] As can be seen from Table 5, when the dosage is lower than that of commercially available praziquantel powder, the therapeutic effects of Examples 1, 2 and 3 of the present invention are significantly higher than that of commercially available praziquantel powder, and there is no significant difference in the therapeutic effects of Examples 1, 2 and 3.
[0093] According to the results of pharmacokinetic tests, the smaller the particle size of praziquantel, the more prominent the effect. Therefore, during large-scale production, the corresponding technical solution will be further confirmed based on the auxiliary materials and processing cost accounting.
[0094] The above implementation examples show that the praziquantel nanopowder of the present invention has the characteristics of good stability, small dosage, high bioavailability and good effect, and has high cost performance for preventing and treating diseases such as schistosomiasis in cattle and sheep, while reducing the risk of drug resistance and drug residues, thereby ensuring the safety of livestock products. The promotion and application and industrialization prospects in large-scale farms and pastoral areas are very broad.
[0095] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A method for preparing a praziquantel nanopowder, characterized in that: The following steps are involved: (1) Weigh a certain amount of praziquantel and add it to an ultrafine grinder to obtain D 50 5-15μm, D 90 20-40 μm praziquantel, for later use; (2) Weigh a certain amount of HPMC and PVPK 30 , sodium lauryl sulfate, dimethyl silicone oil, add purified water to obtain solution A for standby use; (3) Weigh a certain amount of poloxamer, HPMC, and RH 40 , β-cyclodextrin, add purified water to obtain solution B for later use; (4) Add praziquantel to solution A and grind thoroughly to obtain a particle size D 50 100-300nm, D 90 400-600nm praziquantel suspension C; (5) Add praziquantel suspension C to solution B, shear and stir to obtain a particle size D 50 100-300nm, D 90 400-600nm praziquantel nanosuspension D; (6) The praziquantel nanosuspension D is spray dried, powdered, and passed through a 300-mesh sieve to obtain a praziquantel nanopowder.
2. The method for preparing a praziquantel nanopowder according to claim 1, characterized in that: The praziquantel in step (1) and the HPMC and PVPK in step (2) 30 The mass ratio of sodium dodecyl sulfate, dimethyl silicone oil and purified water is (20-40):(0.2-0.4):(0.1-0.3):(0.25-0.75):(1.5-4.5):
100.
3. The method for preparing a praziquantel nanopowder according to claim 1, characterized in that: The praziquantel in step (1) and the poloxamer, HPMC, RH in step (3) 40 The mass ratio of β-cyclodextrin and purified water is (20-40):(4-6):(1-3):(2-4):(11-21):
100.
4. The method for preparing a praziquantel nanopowder according to claim 1, characterized in that: In step (4), the grinding equipment is selected from a colloid mill, a high-pressure homogenizer, and a sand mill, and the grinding time is 2-4 hours.
5. The method for preparing a praziquantel nanopowder according to claim 1, characterized in that: In step (5), the shearing and stirring conditions are 2900r / min, 40-60min.
6. The method for preparing a praziquantel nanopowder according to claim 1, characterized in that: In step (6), the spray drying is set to have an inlet air temperature of 100-130°C, an outlet air temperature of 60-90°C, a steam pressure of 0.05-0.10 MPa, a nozzle pressure of 0.03-0.05 MPa, and a pressure tank temperature of 60-90°C.
7. The method for preparing a praziquantel nanopowder according to claim 6, characterized in that: In step (6), the spray drying is set at an inlet air temperature of 110-120°C and an outlet air temperature of 70-80°C.
8. A praziquantel nanopowder, characterized in that: The praziquantel nanopowder is obtained by the preparation method according to any one of claims 1 to 7.
9. The praziquantel nanopowder according to claim 8, characterized in that: The praziquantel nano powder is dissolved in water at a mass ratio of 1:100, and the particle size D is detected by a laser particle size analyzer. 50 100-300nm, D 90 400-600nm.
10. An application of praziquantel nanopowder, characterized in that: Use of the praziquantel nanopowder according to any one of claims 8 to 9 in anthelmintics for tapeworms and trematodes of cattle, sheep, pigs, poultry, dogs and cats.
Citation Information
Patent Citations
Praziquantel premix and preparation method thereof
CN106377504A
Praziquantel-containing oral medicament
CN107753425A
Method capable of accelerating dissolution rate of praziquantel in water
CN119215178A
Continuous release medicine composition and its preparation method
CN1557318A
Continuous Complexation of Active Pharmaceutical Ingredients
US20190060486A1
